Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
IGF
>>
Phase 2
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
5
10
15
20
25
30
35
40
45
50
cixutumumab
(IMC A12) / Eli Lilly
Oratrope
(ibutamoren) / Merck (MSD), Lumos Pharma
xentuzumab
(BI-836845) / Boehringer Ingelheim
BMS-754807
/ BMS
Premiplex
(mecasermin rinfabate) / Oak Hill Bio, Chiesi
dusigitumab
(MEDI-573) / AstraZeneca
picropodophyllin
(AXL1717) / Axelar
robatumumab
(SCH 717454) / Merck (MSD)
EP-201
/ EpiThany, Aston Sci.
atesidorsen
(ATL1103) / Antisense Therap, Ionis
istiratumab
(MM-141) / Ipsen
LX-101
/ Lirum Therap
scp776
/ Silver Creek Pharma
FPI-1434
/ AstraZeneca
IGV-001
/ Imvax
lonigutamab
(VB421) / Pierre Fabre, ACELYRIN
lonigutamab ugodotin
(W0101) / Pierre Fabre, Roche
